Avadel Pharmaceuticals PLC. (AVDL) Price Target Raised to $30.00 at Ladenburg Thalmann Financial Services
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) had its price target boosted by Ladenburg Thalmann Financial Services from $27.00 to $30.00 in a report released on Thursday, September 7th. Ladenburg Thalmann Financial Services’ price objective would suggest a potential upside of 179.07% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Avadel Pharmaceuticals PLC. from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, July 17th. Roth Capital set a $15.00 price objective on Avadel Pharmaceuticals PLC. and gave the stock a “buy” rating in a research report on Wednesday, August 9th.
Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.140% on Thursday, reaching $11.195. The company had a trading volume of 122,037 shares. The company’s 50 day moving average price is $9.30 and its 200-day moving average price is $9.78. The company has a market capitalization of $448.74 million, a price-to-earnings ratio of 12.168 and a beta of 1.47. Avadel Pharmaceuticals PLC. has a 12 month low of $8.14 and a 12 month high of $13.25.
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. Avadel Pharmaceuticals PLC. had a return on equity of 29.84% and a net margin of 21.13%. The firm’s revenue was up 19.0% compared to the same quarter last year. On average, equities analysts predict that Avadel Pharmaceuticals PLC. will post $1.16 earnings per share for the current fiscal year.
In other news, Director Peter J. Thornton purchased 5,155 shares of the firm’s stock in a transaction dated Thursday, September 21st. The stock was bought at an average price of $9.74 per share, with a total value of $50,209.70. Following the acquisition, the director now directly owns 5,155 shares of the company’s stock, valued at $50,209.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael S. Anderson purchased 4,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was purchased at an average cost of $9.80 per share, with a total value of $39,200.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 46,855 shares of company stock valued at $445,058 in the last ninety days. Company insiders own 5.07% of the company’s stock.
A number of institutional investors have recently modified their holdings of AVDL. State Street Corp lifted its holdings in Avadel Pharmaceuticals PLC. by 1.7% during the second quarter. State Street Corp now owns 31,782 shares of the company’s stock worth $351,000 after acquiring an additional 523 shares in the last quarter. Stifel Financial Corp increased its holdings in shares of Avadel Pharmaceuticals PLC. by 4.3% in the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock worth $667,000 after acquiring an additional 2,500 shares in the last quarter. Sei Investments Co. raised its position in shares of Avadel Pharmaceuticals PLC. by 29.5% during the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after purchasing an additional 2,900 shares during the period. Trexquant Investment LP raised its position in shares of Avadel Pharmaceuticals PLC. by 30.7% during the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock worth $336,000 after purchasing an additional 7,169 shares during the period. Finally, Columbus Circle Investors raised its position in shares of Avadel Pharmaceuticals PLC. by 16.7% during the second quarter. Columbus Circle Investors now owns 51,137 shares of the company’s stock worth $564,000 after purchasing an additional 7,315 shares during the period. 69.09% of the stock is currently owned by institutional investors and hedge funds.
Avadel Pharmaceuticals PLC. Company Profile
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.
Receive News & Stock Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related stocks with our FREE daily email newsletter.